Material and methods
We have reviewed all RA patients treated with biologicals from 1998 to January 2010. We include all patients with at least 6 months of follow up and analyze clinical efficacy as improvement in DAS count. We registered the cause for switch among biologic drugs and the response to a new biologic. Our hospital attends about 350.000 inhabitants and the prevalence of RA in Spain, as settled by Spanish Society for Rheumatology is 0.5%, so we could expect to have about 1800 RA patients, so we are treating about 12% of RA patients with biologicals.
Results
We have reviewed 206 patients, 68% female, mean age 56.5, average duration of the disease 10.8 years. RF positive 79.3% CCP 68.2%, erosive 58.2%. Initial DAS was 5.8 and at the end evaluation 53,6% of patients have a DAS<2.6.
Etanercept was the most used at onset (58%), 76 patients (36.4%) switched for inefficacy (62%) or side effects (21.7%).
Side effects were registered in 39%, with drug stop in 81% and hospital admission in 18.9%. The more common side effects were reactions at the injection site 33%, infectious processes 23.1% and skin alterations 17.9%.
Conclusions
The disease activity was high when biologic started, (DAS 5.8) . The main cause of switching is loss of efficacy. Etanercept is the more prescribed drug to initiate biologic therapy.
Rituximab and Etanercept are used as a second option in the majority of patients. Abatacept is used only after a second switch. The improvement of patients is notorious with RA remission by DAS<2.6 in 53,6% of patients. The frequency of switch biologics is similar to other registry experiences.
